IP Library Granted Patent US 9,388,233
Granted Patent B2
US 9,388,233 · App. 13/192,407 · Granted Jul 12, 2016

Rat having a disrupted immunoglobulin gene

Inventor: Roland Buelow (Palo Alto, CA)
C07K16/00A01K67/0278C12N9/22C12N15/8509A01K2217/072A01K2267/01
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,388,233
App. No.
13/192,407
Granted
Jul 12, 2016
Kind
B2
Abstract

The invention relates to transgenic animals lacking endogenous Ig and capable of producing transgenic antibodies, as well as methods of making the same. The invention further relates to methods for producing transgenic antibodies in such animals, and transgenic antibodies so produced.

Claims (5)

1. A transgenic rat whose genome comprises a functionally ablated endogenous immunoglobulin (Ig) heavy chain gene and/or a functionally ablated endogenous Ig light chain gene.

2. The transgenic rat according to claim 1 whose genome further comprises a nucleic acid sequence encoding an exogenous human Ig gene capable of producing immunoglobulins with human idiotypes.

3. The transgenic rat according to claim 2 , wherein the exogenous human Ig gene is an Ig light chain gene and/or an Ig heavy chain gene.

4. The transgenic rat according to claim 2 , wherein the exogenous human Ig gene comprises human immunoglobulin gene segments and rat immunoglobulin gene segments, wherein the human immunoglobulin gene segments comprise: (i) at least one human variable (V) gene segment and/or (ii) at least one human diverse (D) gene segment.

5. The transgenic rat according to claim 4 , wherein the human immunoglobulin gene segments comprise a nucleic acid sequence selected from the group consisting of: i) naturally occurring human Ig gene sequences; ii) degenerate forms of naturally occurring human Ig gene sequences; and iii) synthetic sequences encoding a polypeptide sequence that is 85%-95% identical to the polypeptide encoded by a naturally occurring human Ig gene sequence.

Assignments (4)
CHANGE OF NAME Recorded Nov 16, 2022
From: OMNIAB, INC.
To: OMNIAB OPERATIONS, INC.
Reel/Frame 061954/0460 →
CHANGE OF NAME Recorded Mar 17, 2022
From: OPEN MONOCLONAL TECHNOLOGY, INC.
To: OMNIAB, INC.
Reel/Frame 059435/0056 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY'S NAME PREVIOUSLY RECORDED AT REEL: 037830 FRAME: 0484. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Nov 18, 2016
From: BUELOW, ROLAND, PH.D
To: OPEN MONOCLONAL TECHNOLOGY, INC.
Reel/Frame 040648/0034 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2016
From: BUELOW, PH.D., ROLAND
To: OMT, INC.
Reel/Frame 037830/0484 →
Continuity (4)
Division 12130818 · May 30, 2008
Provisional Application 61044324 · Apr 11, 2008
Provisional Application 60941619 · Jun 1, 2007
Related Publication 20120090041A1 · Apr 12, 2012